New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:03 EDTCGENCompugen reports Q1 EPS (4c), consensus (10c)
Reports Q1 revenue $2.13, consensus $1.84M. The company said, "Cost of revenues for Q1 were $757K, compared with $150K for the comparable period in FY13. This increase reflects, in large part, research and development expenses attributed to our ongoing collaboration agreements."
News For CGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
07:12 EDTCGENCompugen to focus on ongoing programs during 2016
Company said, "This past year was a year of significant accomplishment for our company with respect to our unique discovery infrastructure and our target pipeline program. Another key achievement was the aggressive advancement of a second immune checkpoint program, CGEN-15029, which is our leading internal immuno-oncology program. Looking ahead, with substantially expanded capabilities and capacity, during 2016 our R&D focus will be on the advancement of these programs, the addition of immuno-oncology programs based on targets now undergoing validation, and further target discovery efforts."
07:10 EDTCGENCompugen reports Q4 EPS (1c), consensus (11c)
Subscribe for More Information
February 1, 2016
07:28 EDTCGENCompugen coverage assumed with an Outperform at Oppenheimer

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use